Think BIG Bodybuilding Blood Sweat & Gear 329 Why Lifters Are Switching Compounds — PED Trends That Will Define 2026
Jan 2, 2026
Discover the 2026 trends in PEDs and peptides, with rising popularity for DHB and Equipoise. The hosts dive into heavy metal contamination in UGL steroids and cycle critiques, offering insightful feedback on dosages. Learn about the impact of low-dose cycles and the growing acceptance of certain peptides. They also discuss effective fat-loss strategies and high-volume training techniques. Plus, hear a compelling story from an older competitor and the challenges faced in Canada regarding lab testing.
AI Snips
Chapters
Transcript
Episode notes
Lower Tren Dosing Became The Norm
- The industry shifted toward lower trenbolone dosing as a broader trend in 2025.
- Competitors now start low (25–50 mg) and increase if needed rather than defaulting to high doses.
Equipoise Rising As DHT Options Drop
- Equipoise (EQ) is rising as mast and primo became less available, partly because of EQ's estrogen-control effects.
- Greater awareness of compound side effects also makes users more likely to self-diagnose and report reactions.
DHB Adoption Is Growing
- DHB is becoming a household name for 2026 as earlier fears (PIP, liver inflammation) are being challenged.
- Scott and Andrew expect DHB use to grow as myths are dispelled and sourcing improves.